Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...
A research team has developed a multi-medium approach (MMA) to identify reproducible volatile organic compounds (VOCs) in ...
News Medical on MSN15h
DNA’s organization influences the risk of smoking-induced lung cancerThe study from The Hebrew University of Jerusalem, led by Prof. Sheera Adar and her graduate student Elisheva Heilbrun-Katz ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...
The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback